Venetoclax Extension Study

JRCT ID: jRCT2051220047

Registered date:10/06/2022

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Multiple Myeloma
• Date of first enrollment: 06/07/2022
• Target sample size: 550
• Countries of recruitment: United States,Japan,Australia,Japan,Austria,Japan,Belgium,Japan,Canada,Japan,Denmark,Japan,France,Japan,Greece,Japan,Hong Kong,Japan,Ireland,Japan,Mexico,Japan,New Zealand,Japan,Poland,Japan,Portugal,Japan,Russian Federation,Japan,Spain,Japan,Sweden,Japan,Taiwan,Japan,Turkey,Japan,United Kingdom,Japan
• Study type: Interventional
• Intervention(s): Venetoclax

Outcome(s)

• Primary Outcome: Adverse Events

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Both

Include criteria

- Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- Male subject agrees to refrain from sperm donation.
- Female subjects must not be pregnant or breastfeeding.

• Exclude criteria: - None

Related Information

• Primary Sponsor: Sumiko Okubo
• Secondary ID(s): NCT03844048